The U.S. Food and Drug Administration approved Pfizer Inc.’s Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers.
Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.
Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.
Novartis announced detailed results from the Phase III PREVENT trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondyloarthritis.
A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.
A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib in Phase 3 Studies for Rheumatoid Arthritis
Arthritis, Clinical Data, Clinical Trials, European Medicines Agency, FDA, Inflammatory Diseases, JAK1 Inhibitors, Marketing Authorization Application (MAA), New Drug Application (NDA), New Drug Applications, R&D, Rheumatoid ArthritisGilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.
Novartis’ Cosentyx hit the mark in treating patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a Phase III trial.
Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.
IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.